|
| 37246588 | Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. | Br J Haematol | 2023 |
| 37895201 | Complex Genomic Rearrangements Involving <i>ETV6</i>::<i>ABL1</i> Gene Fusion in an Individual with Myeloid Neoplasm. | Genes (Basel) | 2023 |
| 34491344 | Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. | J Natl Cancer Inst | 2022 |
| 35511672 | Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. | Haematologica | 2022 |
| 36054756 | Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. | Am J Hematol | 2022 |
| 32414851 | Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. | Haematologica | 2021 |
| 33626861 | The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment. | Haematologica | 2021 |
| 34479037 | Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor. | Eur J Med Chem | 2021 |
| 34103301 | Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. | Clin Cancer Res | 2021 |
| 33180106 | Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. | JAMA Oncol | 2021 |
| 33022644 | Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2020 |
| 31647335 | Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. | Leuk Lymphoma | 2020 |
| 31088841 | Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. | Cancer Discov | 2019 |
| 30093398 | Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. | Haematologica | 2019 |
| 31270078 | ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT. | Cancer Res | 2019 |
| 31117031 | NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia. | J Natl Compr Canc Netw | 2019 |
| 29206554 | Front-Line Treatment Options for Chronic-Phase Chronic Myeloid Leukemia. | J Clin Oncol | 2018 |
| 29859851 | Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. | Lancet Oncol | 2018 |
| 30181422 | Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2018 |
| 29609532 | Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. | BMC Cancer | 2018 |
| 29567798 | Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. | Blood | 2018 |
| 29487300 | Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT. | Sci Rep | 2018 |
| 27890928 | Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors. | Leukemia | 2017 |
| 28490572 | Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis. | Blood | 2017 |
| 28534184 | Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. | Ann Hematol | 2017 |
| 28667329 | Imipramine blue sensitively and selectively targets FLT3-ITD positive acute myeloid leukemia cells. | Sci Rep | 2017 |
| 26998677 | Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. | Cancer | 2016 |
| 26603839 | Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. | Blood | 2016 |
| 26511402 | Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib. | Leukemia | 2016 |
| 26585411 | Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone. | Leukemia | 2016 |
| 27956535 | NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. | J Natl Compr Canc Netw | 2016 |
| 27192969 | Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. | Am J Hematol | 2016 |
| 27217448 | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. | J Clin Oncol | 2016 |
| 27158668 | The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. | JCI Insight | 2016 |
| 26686247 | Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. | Leukemia | 2016 |
| 27083332 | Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. | Lancet Oncol | 2016 |
| 25765758 | Computer aided drug discovery of highly ligand efficient, low molecular weight imidazopyridine analogs as FLT3 inhibitors. | Eur J Med Chem | 2015 |
| 26461088 | PPARγ: Welcoming the New Kid on the CML Stem Cell Block. | Cancer Cell | 2015 |
| 26419724 | Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. | Sci Rep | 2015 |
| 26284693 | Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. | Am J Hematol | 2015 |
| 26108694 | FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. | Leukemia | 2015 |
| 25870379 | Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. | J Natl Compr Canc Netw | 2015 |
| 25847190 | Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397. | Cancer Discov | 2015 |
| 24131888 | Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. | Leuk Res | 2014 |
| 25768408 | Integrating current treatment options for TKI-resistant chronic myeloid leukemia. | Clin Adv Hematol Oncol | 2014 |
| 25456130 | Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. | Cell Rep | 2014 |
| 25531068 | Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. | Elife | 2014 |
| 25361806 | Chronic myelogenous leukemia, version 1.2015. | J Natl Compr Canc Netw | 2014 |
| 25166742 | Sensitive and selective plasmon ruler nanosensors for monitoring the apoptotic drug response in leukemia. | ACS Nano | 2014 |
| 24584101 | Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. | Nat Chem Biol | 2014 |